Crohn's Disease Market Size is anticipated to grow at a CAGR of 7.6% for the study period 2018–2030 | DelveInsight

Crohn’s disease is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus. Additionally, ulcerative colitis, an IBD that causes long-lasting inflammation and ulcers (sores) in your digestive tract, is limited to the colon, also called the large intestine. CROHN’S DISEASE is characterized by skip intestinal lesions (that is, areas of inflammation interposed between normal-appearing mucosa) anywhere in the GI tract. It involves chronic, relapsing transmural inflammation that can lead to Chronic abdominal pain, diarrhea, obstruction and/or perianal lesions.

DelveInsight’s ‘Crohn’s Disease Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the Crohn’s Disease, historical and forecasted epidemiology as well as the Crohn’s Disease market trends in the United States.

Some facts of Crohn’s Disease Market are:

·         In the year 2020, the total prevalent case of Crohn’s Disease was 825,165 cases in the United States which are expected to grow during the forecast period, i.e., 2021–2030.

·         The disease epidemiology covered in the report provides historical as well as forecasted Crohn’s Disease epidemiology [segmented as Total Prevalent Cases of Crohn’s Disease, Total Diagnosed Cases of Crohn’s Disease, Age-specific cases of Crohn’s Disease, Severity-specific Cases of Crohn’s Disease, and Treated cases of Crohn’s Disease] in the United States from 2018 to 2030.

·         The US FDA-approved biologics for the treatment of Crohn’s Disease include infliximab, adalimumab, certolizumab, vedolizumab, natalizumab, ustekinumab.

·         Growth of the Crohn’s Disease market is expected to be mainly driven by the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/advanced therapies, advances in research and development, new biomarkers for diagnosis of Crohn’s Disease, and increasing prevalence of Crohn’s Disease.

View Report: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Request for Sample Report: https://www.delveinsight.com/sample-request/crohns-disease-cd-market

Crohn’s Disease Report Scope

  • The report covers the descriptive overview of Crohn’s Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Crohn’s Disease epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Crohn’s Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Crohn’s Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Crohn’s Disease market

Crohn’s Disease Therapies covered:

·         Jyselica/Filgotinib (Gilead Sciences/Galapagos NV)

·         Rinvoq/Upadacitinib (AbbVie)

·         Etrolizumab/RG 7413 (Hoffmann-La Roche/Genentech)

·         Ozanimod/Zeposia (Celgene)

·         Skyrizi/Risankizumab (AbbVie/Boehringer Ingelheim)

·         Brazikumab/MEDI-2070 (Astrazeneca)

·         Alofisel/Darvadstrocel (Takeda/TiGenix)

·         Mirikizumab/LY-3074828 (Eli Lilly and Company)

·         RHB-104 (RedHill Biopharma)

·         Etrasimod/APD334 (Arena Pharmaceuticals)

·         Tremfya/Guselkumab (Janssen)

·         Deucravacitinib/BMS-986165 (Bristol-Myers Squibb)

·         Tesnatilimab/JNJ-64304500 (Janssen)

·         Sibofimloc/EB8018 (Takeda/Enterome)

·         BT-11 (Landos Biopharma)

·         UTTR1147A/RG 7880 (Genentech)

·         TD-1473/JNJ 8398 (Theravance Biopharma/Janssen)

·         JNJ-67864238/PTG 200 (Protagonist Therapeutics/Janssen)

·         SHR0302 (Reistone Biopharma)

·         Ryoncil/Remestemcel-L (Mesoblast)

·         Ritlecitinib/Brepocitinib (Pfizer)

View Report: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Request for Sample Report: https://www.delveinsight.com/sample-request/crohns-disease-cd-market

Table of content

  1. Key Insights
  2. Executive Summary of Crohn’s Disease
  3. Competitive Intelligence Analysis for Crohn’s Disease
  4. Crohn’s Disease: Market Overview at a Glance
  5. Crohn’s Disease: Disease Background and Overview
  6. Patient Journey
  7. Crohn’s Disease Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Crohn’s Disease Treatment
  11. Marketed Products
  12. Emerging Therapies
  13. Crohn’s Disease: Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview of Crohn’s Disease
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

View Report: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Request for Detailed TOC: https://www.delveinsight.com/sample-request/crohns-disease-cd-market

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Crohn’s Disease market
  • To understand the future market competition in the Crohn’s Disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Crohn’s Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Crohn’s Disease market
  • To understand the future market competition in the Crohn’s Disease market

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech, and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Related Reports:

·         Intrahepatic Cholangiocarcinoma Market

·         Barett Esophagus Market

·         Aortic Stenosis Market

·         Chemotherapy Induced Diarrhea Market

·         Immunologic Deficiency Syndrome Market

·         Binge Eating Disorder Market

·         Acquired Immunodeficiency Syndrome (AIDS) Market

·         Bladder pain syndrome Market

·         Cardiac Arrythmia Market

·         Cardiorenal Syndrome Market

·         Carpal Tunnel Syndrome Market

·         Central Retinal Venous Occulsion Market

·         Foot and Ankle Devices Market

 

Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t...
Read more

The Need And The Importance Of The Healthcare Reports for the Pharma Companies

Image
It is very important for the hospitals and the other medical institutions to preserve and keep the healthcare reports of all the patients very safe and secure. All the medical records are being kept by almost all of these institutes. As a matter of fact, the healthcare reports are very important for comprehending the medical history of the patient. If he or she suffers from the same ailment once more the previous reports will be absolutely indispensible while treating him or her. Nowadays, with the advancement of technology the manual records are slowly and gradually getting digitalized. It is easier to store and preserve the digital records than the manual and the physical ones.  Choosing The Best And The Most Professional Services For Healthcare Reports: • Rising Pharma Market for You Now In the market there are a host of companies that preserves the healthcare reports of the various patients. All of it is now being done in the digital format due to the adv...
Read more

Vernal Keratoconjunctivitis Market

(Albany, US) DelveInsight’s “ Vernal Keratoconjunctivitis Market  Insights, Epidemiology, and Market Forecast-2030 ” report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Vernal Keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some of the key facts of the  Vernal Keratoconjunctivitis Market The increasing population and rising prevalence of Vernal Keratoconjunctivitis generates a large patient population in the global market. In 2017, a total of 4,752,356 patients were affected by Vernal Keratoconjunctivitis in the global market. China contributes the largest share among EU-5, and Japan, with 2,248,706 cases in 2017. The total diagnosed prevalent population of Vernal Keratoconjunctivitis was 2,943,057 in the global market.   Request for Sample Report: https://www.delveinsight.com/report-store...
Read more